Dyne Therapeutics (NASDAQ: DYN)
$24.65
(4.0%)
$0.96
Price as of April 26, 2024, 1:49 p.m. ET
Dyne Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Dyne Therapeutics Company Info
Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.
News & Analysis
Featured Article
Why Shares of Dyne Therapeutics Fell This Week
Insiders sold more than 15,000 shares of company stock on Tuesday.
Jim Halley | Sep 15, 2023
Featured Article
Why Shares of Dyne Therapeutics Dropped 18.1% on Tuesday
A clinical hold regarding one of the company's therapies brought Dyne's shares to a 52-week low.
Jim Halley | Jan 18, 2022
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.